Why it matters: The agreement adds another mechanism to Roche’s growing obesity pipeline as drugmakers look beyond weight loss alone and focus on preserving muscle.
How it works: HM17321 is a long-acting analog of urocortin-2, or UCN2, a signaling protein involved in metabolic and cardiovascular processes. Unlike GLP-1 drugs, the peptide uses a non-incretin mechanism. Hanmi designed it to reduce fat while preserving lean body mass – a concern with existing obesity treatments – and sees potential for its use alone or alongside GLP-1 therapies.
Preclinical studies linked HM17321 to weight reduction as both a monotherapy and in combination with GLP-1 drugs, according to Hanmi.
Zoom in: The U.S. Food and Drug Administration cleared Hanmi’s investigational new drug application in November 2025. An ongoing Phase 1 trial is assessing safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and people with obesity. Hanmi will complete that study before Genentech takes control of development from Phase 2.
Roche also plans to explore the candidate in conditions associated with obesity, including type 2 diabetes and cardiovascular disease.
Big picture: Last year, Roche unveiled its plan to become a top-three company in obesity. Its pipeline already includes the injectable GLP-1/GIP drug enicepatide, oral GLP-1 candidate CT-996 and petrelintide, an amylin analog partnered with Denmark’s Zealand Pharma.
The Swiss group is also testing the muscle-building antibody emugrobart with Eli Lilly’s Mounjaro in Phase 2. HM17321 gives Roche a second way to tackle the loss of lean mass associated with weight reduction.